Search / Trial NCT06612827

Development of Tumor Organoids from Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions

Launched by CENTRE FRANCOIS BACLESSE · Sep 23, 2024

Trial Information

Current as of October 07, 2024

Not yet recruiting

Keywords

Tumoroid Organoid

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Patient with undifferentiated primary carcinoma (UPC) with histological and immunohistochemical evidence, validated in a local and/or national UPC multidisciplinary consultation
  • * Patient with indication for 1st-line treatment at the time of inclusion.
  • * Patient with life expectancy greater than 3 months
  • * Patient of legal age
  • * Patient affiliated to a social security scheme
  • * Signature of informed consent prior to any specific study procedure
  • Exclusion Criteria:
  • * Persons deprived of their liberty or under guardianship (including curatorship)
  • * Pregnant or breast-feeding patient

About Centre Francois Baclesse

The Centre François Baclesse is a leading cancer research and treatment facility in France, dedicated to advancing oncology through innovative clinical trials and cutting-edge medical care. Renowned for its multidisciplinary approach, the center integrates comprehensive patient management with pioneering research initiatives, focusing on developing new therapies and improving existing treatments for various cancer types. With a commitment to enhancing patient outcomes, the Centre François Baclesse collaborates with national and international partners to contribute to the global body of knowledge in cancer treatment and research, making it a pivotal player in the fight against cancer.

Locations

Caen, , France

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0